OncoMatch/Clinical Trials/NCT06078787
Olaparib in PALB2 Advanced Pancreatic Cancer
Is NCT06078787 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Olaparib 150 MG for advanced pancreatic cancer.
Treatment: Olaparib 150 MG — This is a Phase II, non-randomized, multicenter, unblinded open-label study of Olaparib in monotherapy in participants with advanced (locally advanced/metastatic) PALB2-related pancreatic cancer that have progressed after at least one treatment for advanced disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: PALB2 deleterious or suspected deleterious mutation
documented mutation in PALB2 gene (germline or somatic) that is predicted to be deleterious or suspected deleterious
Excluded: PALB2 benign variant
Has a benign variant of PALB2 gene
Excluded: PALB2 variant of uncertain (or unknown) significance (VUS)
variant of uncertain (or unknown) significance (VUS)
Disease stage
Required: Stage IV (AJCC 8th Edition)
advanced (unresectable or metastatic) pancreatic cancer by American Joint Committee on Cancer 8th Edition
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — advanced disease (locally advanced or metastatic)
Has received at least one systemic treatment for advanced disease (locally advanced or metastatic disease)
Cannot have received: PARP inhibitor (olaparib)
Any previous treatment with PARP inhibitor, including Olaparib
Cannot have received: systemic chemotherapy
Exception: except for palliative reasons
Has prior systemic chemotherapy, targeted small molecule therapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment
Cannot have received: targeted small molecule therapy
Has prior systemic chemotherapy, targeted small molecule therapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment
Cannot have received: radiotherapy
Exception: except for palliative reasons
Has prior systemic chemotherapy, targeted small molecule therapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment
Cannot have received: anti-monoclonal antibody
Has received prior therapy with an anti-monoclonal antibody within 4 weeks or who has not recovered (i.e. <= G1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier
Cannot have received: allogenic bone marrow transplant
Has received previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)
Cannot have received: double umbilical cord blood transplantation
Has received previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)
Cannot have received: whole blood transfusion
Exception: packed red blood cells and platelet transfusions are acceptable if not performed within 28 days of the first dose
Has received a whole blood transfusions in the last 120 days prior to entry to the study. Packed red blood cells and platelet transfusions are acceptable, if not performed within 28 days of the first dose of study intervention
Lab requirements
Blood counts
adequate organ function as defined in Table 2; all screening laboratory tests should be performed within 10 days prior to initiation of study intervention
Kidney function
adequate organ function as defined in Table 2; all screening laboratory tests should be performed within 10 days prior to initiation of study intervention
Liver function
adequate organ function as defined in Table 2; all screening laboratory tests should be performed within 10 days prior to initiation of study intervention
Has adequate organ function as defined in Table 2; all screening laboratory tests should be performed within 10 days prior to initiation of study intervention
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify